Oxaliplatin, Capecitabine, Cisplatin, Leucovorin, 5-Fluorouracil (5-FU), Subcutaneous Tislelizumab, Intravenous Tislelizumab
Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma